Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?

被引：6
|
作者：
Nipp, Ryan D. [1 ]
Ryan, David P. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
来源：
ONCOLOGIST | 2015年 / 20卷 / 03期
关键词：
PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; INFUSIONAL FLUOROURACIL; OXALIPLATIN; FOLFIRI; LEUCOVORIN; CHEMOTHERAPY; STATISTICS; IRINOTECAN; CETUXIMAB;
D O I：
10.1634/theoncologist.2014-0495
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：236 / 238
页数：3
相关论文
共 50 条
  • [1] Intensified First Line Therapy of the metastatic colorectal Cancer with FOLFOXIRI plus Bevacizumab
    Ruessel, J.
    [J]. ONKOLOGE, 2015, 21 (04): : 334 - 335
  • [2] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [3] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    [J]. CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [4] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [5] FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] FOLFOXIRI plus Bevacizumab in metastatic colorectal Cancer
    不详
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (07): : 630 - 630
  • [8] A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
    Oki, Eiji
    Kato, Takeshi
    Bando, Hideaki
    Yoshino, Takayuki
    Muro, Kei
    Taniguchi, Hiroya
    Kagawa, Yoshinori
    Yamazaki, Kentaro
    Yamaguchi, Tatsuro
    Tsuji, Akihito
    Iwamoto, Shigeyoshi
    Nakayama, Goro
    Emi, Yasunori
    Touyama, Tetsuo
    Nakamura, Masato
    Kotaka, Masahito
    Sakisaka, Hideki
    Yamanaka, Takeharu
    Kanazawa, Akiyoshi
    [J]. CLINICAL COLORECTAL CANCER, 2018, 17 (02) : 147 - 155
  • [9] Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Fioravanti, A.
    Orlandi, P.
    Salvatore, L.
    Masi, G.
    Di Desidero, T.
    Canu, B.
    Schirripa, M.
    Frumento, P.
    Di Paolo, A.
    Danesi, R.
    Falcone, A.
    Bocci, G.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (08) : 1262 - 1269
  • [10] Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
    F Loupakis
    C Cremolini
    A Fioravanti
    P Orlandi
    L Salvatore
    G Masi
    T Di Desidero
    B Canu
    M Schirripa
    P Frumento
    A Di Paolo
    R Danesi
    A Falcone
    G Bocci
    [J]. British Journal of Cancer, 2011, 104 : 1262 - 1269
12345